CX Institutional’s Novavax NVAX Stock Holding History

CX Institutional’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-460	Closed	-$3K	–	1392
2025 Q2	$3K	Hold	460	–	–	﹤0.01%	1130
2025 Q1	$3K	Buy	+460	New	+$3.8K	﹤0.01%	1114
2021 Q1	–	Sell	-460	Closed	-$51K	–	877
2020 Q4	$51K	Buy	+460	New	+$48.9K	﹤0.01%	438

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CX Institutional's NVAX Position: Q3 2025 in Review

CX Institutional sold out of Novavax (NVAX) in Q3 2025, closing a stake of 460 shares — an estimated $3K sold.

CX Institutional first reported a position in NVAX in Q4 2020 and held it in 3 quarters. The position peaked at $51K in Q4 2020. 249 funds tracked by Wall St. Rank hold NVAX as of Q3 2025.

CX Institutional reported no remaining Novavax position as of Q3 2025 after selling out during the quarter.
CX Institutional sold 460 Novavax shares in Q3 2025, an estimated $3K.
CX Institutional first reported a position in Novavax in Q4 2020 and held it in 3 quarters.
CX Institutional's Novavax position peaked at $51K in Q4 2020.
249 funds tracked by Wall St. Rank held Novavax as of Q3 2025.

Based on CX Institutional's 13F filing for Q3 2025, filed 23 Oct 2025.